Levosimendan Tillomed

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer / inodilator presented as an intravenous formulation for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients who require rapid hemodynamic support.

GNH USA supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of acute heart failure syndromes, acting as a calcium sensitizer and vasodilator to improve cardiac performance.

- Acute decompensated heart failure: enhances myocardial contractility and reduces pulmonary congestion. - Cardiogenic shock: provides inotropic support while lowering systemic vascular resistance. - Low‑output heart failure after cardiac surgery: stabilises haemodynamics and facilitates weaning from mechanical support.

Levosimendan may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Hypotension: drop in blood pressure, especially when combined with other vasodilators. - Headache: transient, often related to vasodilation. - Nausea: mild gastrointestinal upset. - Tachycardia: increased heart rate. - Arrhythmia: premature beats or mild rhythm disturbances.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes. - Ventricular arrhythmias: potentially life‑threatening rhythm disorders. - Anaphylactic reaction: rare allergic response. - Hepatic enzyme elevation: significant liver function test changes.

Levosimendan should be administered with careful clinical monitoring and consideration of patient‑specific factors. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; observe liver enzymes. - Hypotension: measure blood pressure frequently during infusion. - Concurrent vasodilators: increased risk of additive blood pressure fall. - Arrhythmias: continuous ECG monitoring is recommended. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several cardiovascular agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilatory effect leading to profound hypotension. - Phosphodiesterase‑3 inhibitors (e.g., milrinone): risk of excessive inotropic and vasodilatory response. - Strong CYP3A4 inhibitors: may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor for enhanced hypotensive effect. - Loop diuretics: watch for electrolyte disturbances and blood pressure changes. - Calcium channel blockers: observe for altered vascular tone and heart rate.